What do we know about IDH1/2 mutations so far, and how do we use it?

Area of Science:

• Oncology
• Genetics
• Biochemistry

Background:

• Whole genome analyses have identified key genetic alterations in diseases, particularly cancer.
• Mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) are prevalent in gliomas and other neoplasms.

Purpose of the Study:

• To discuss the normal functions of IDH1/2 enzymes.
• To explain how mutations alter enzyme properties and their D-2-hydroxyglutarate metabolite.
• To review diagnostic, prognostic, and therapeutic implications of IDH1/2 mutations.

Main Methods:

• Literature review and synthesis of existing research on IDH1/2 mutations.
• Analysis of biochemical properties and clinical data related to IDH1/2 alterations.

Main Results:

• IDH1/2 mutations alter enzyme function, leading to the production of D-2-hydroxyglutarate.
• These mutations have significant prognostic and therapeutic implications in glioma and other cancers.
• Diagnostic testing for IDH1/2 mutations is crucial for patient management.

Conclusions:

• IDH1/2 mutations are critical biomarkers in oncology.
• Understanding these mutations aids in developing targeted therapies and improving patient outcomes.
• Standardized testing and interpretation of IDH1/2 mutations are essential for clinical practice.